- Ruxolitinib, sold
under the
brand name
Jakafi among others, is a
medication used for the
treatment of
intermediate or high-risk myelofibrosis, a type of...
-
November 2011, the US Food and Drug
Administration (FDA)
approved ruxolitinib (
Jakafi) as a
treatment for
intermediate or high-risk myelofibrosis. Ruxolitinib...
-
formulation of
Exjade (which
comes in
tablets for oral suspension) Jakavi/
Jakafi (ruxolitinib)
Myelofibrosis (of
intermediate to high risk)
Kisqali (ribociclib)...
-
anagrelide (Agrylin). In J****
kinase 2
positive disorders,
ruxolitinib (
Jakafi) can be effective.[citation needed]
Kumar PJ,
Clark ML (2005). "8". Clinical...
-
option for
those with
certain genetic markers.
Ruxolitinib (brand name
Jakafi), a J****
kinase 2 (JAK2) inhibitor, is also used to
treat polycythemia...
- 2397–407. doi:10.1517/14656566.2012.732998. PMID 23051187. S2CID 29293800. "
Jakafi (ruxolitinib) Tablets, for Oral Use. Full
Prescribing Information" (PDF)...
-
currently has
seven marketed and co-marketed
pharmaceutical products,
including Jakafi (ruxolitinib),
Pemazyre (pemigatinib),
Monjuvi (tafasitamab-cxix), Opzelura...
- | S | T | U | V | W | X | Y | Z
Jadelle Jadenu Sprinkle Jadenu Jaimiess Jakafi Jalyn Jamteki Janimine Jantoven Janumet XR
Janumet Januvia Jardiance Jatenzo...
-
myeloproliferative neoplasms and psoriasis". IDrugs. 13 (6): 394–403. PMID 20506062. "
Jakafi-
ruxolitinib tablet". DailyMed. 26
February 2020.
Archived from the original...
